TEVA Teva Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$8.53

Market cap

$9.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.12

Enterprise value

$28.24B

Highlights
The debt has declined by 8% year-on-year
TEVA's quick ratio is up by 10% from the previous quarter but it is down by 7% YoY
Teva Pharmaceutical Industries's EPS has shrunk by 83% QoQ
TEVA's net income has dropped by 82% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Peers: PFE MRK

Key stats

What are the main financial stats of TEVA
Market
Shares outstanding
1.11B
Market cap
$9.48B
Enterprise value
$28.24B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.2
Price to sales (P/S)
0.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.89
Earnings
Revenue
$14.93B
EBIT
-$2.03B
EBITDA
-$717M
Free cash flow
$1.04B
Per share
EPS
-$2.12
Free cash flow per share
$0.94
Book value per share
$7.11
Revenue per share
$13.45
TBVPS
$18.11
Balance sheet
Total assets
$44.01B
Total liabilities
$35.32B
Debt
$21.56B
Equity
$7.9B
Working capital
$582M
Liquidity
Debt to equity
2.73
Current ratio
1.05
Quick ratio
0.57
Net debt/EBITDA
-26.16
Margins
EBITDA margin
-4.8%
Gross margin
46.7%
Net margin
-15.8%
Operating margin
-14.8%
Efficiency
Return on assets
-5.2%
Return on equity
-26.9%
Return on invested capital
-7.1%
Return on capital employed
-6.2%
Return on sales
-13.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TEVA stock price

How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
-2.29%
1 week
0.35%
1 month
-14.79%
1 year
5.18%
YTD
-6.47%
QTD
-6.47%

Financial performance

How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$14.93B
Gross profit
$6.97B
Operating income
-$2.21B
Net income
-$2.35B
Gross margin
46.7%
Net margin
-15.8%
The net margin has dropped by 86% since the previous quarter
TEVA's net income has dropped by 82% since the previous quarter
The operating margin has shrunk by 74% QoQ
TEVA's operating income has plunged by 72% from the previous quarter

Growth

What is Teva Pharmaceutical Industries's growth rate over time

Valuation

What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
1.2
P/S
0.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.89
Teva Pharmaceutical Industries's EPS has shrunk by 83% QoQ
Teva Pharmaceutical Industries's equity has decreased by 23% YoY and by 10% QoQ
TEVA's price to book (P/B) is 23% higher than its 5-year quarterly average of 1.0 and 12% higher than its last 4 quarters average of 1.1
The P/S is 8% above the last 4 quarters average of 0.6 but 7% below the 5-year quarterly average of 0.7
TEVA's revenue is down by 6% year-on-year

Efficiency

How efficient is Teva Pharmaceutical Industries business performance
TEVA's ROE has plunged by 95% from the previous quarter
Teva Pharmaceutical Industries's return on assets has shrunk by 86% QoQ
The company's return on invested capital has shrunk by 82% QoQ
Teva Pharmaceutical Industries's return on sales has shrunk by 81% QoQ

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Teva Pharmaceutical Industries financials performed over time
The total assets is 25% greater than the total liabilities
TEVA's quick ratio is up by 10% from the previous quarter but it is down by 7% YoY
The total assets is down by 8% year-on-year
The debt is 173% greater than the equity
Teva Pharmaceutical Industries's equity has decreased by 23% YoY and by 10% QoQ
TEVA's debt to equity is up by 20% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.